In a filing, Intellia Therapeutics Inc revealed its EVP, Chief Scientific Officer Schultes Birgit C unloaded Company’s shares for reported $539.0 on Oct 01 ’25. In the deal valued at $17.38 per share,31 shares were sold. As a result of this transaction, Schultes Birgit C now holds 105,184 shares worth roughly $2.16 million.
Then, Dube Michael P sold 1,871 shares, generating $32,518 in total proceeds. Upon selling the shares at $17.38, the VP, Chief Accounting Officer now owns 55,266 shares.
Before that, CHASE WILLIAM J bought 100,000 shares. Intellia Therapeutics Inc shares valued at $1,003,000 were divested by the Director at a price of $10.03 per share. As a result of the transaction, CHASE WILLIAM J now holds 134,693 shares, worth roughly $2.77 million.
Citizens JMP upgraded its Intellia Therapeutics Inc [NTLA] rating to a Mkt outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in late April from “a Peer perform” to “an Outperform”. H.C. Wainwright began covering NTLA with “Buy” recommendation on March 05, 2025. JP Morgan revised its rating on February 28, 2025. It rated NTLA as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of NTLA
On Monday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock jump 2.91% to $20.54. Over the last five days, the stock has gained 21.39%. Intellia Therapeutics Inc shares have risen nearly 10.73% since the year began. Nevertheless, the stocks have risen 76.16% over the past one year. While a 52-week high of $21.47 was reached on 10/06/25, a 52-week low of $5.90 was recorded on 04/07/25.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 20.11, which if violated will result in even more drops to 19.69. On the upside, there is a resistance level at 21.23. A further resistance level may holdings at 21.92.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-09-15, growing by 6.41 million shares to a total of 34.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 27.73 million shares. There was a rise of 18.77%, which implies that there is a positive sentiment for the stock.
